What these results show is that someone who got this vaccine would have an extra boost of protection against symptomatic infection from both the XBB variant that was common in the fall, as well as JN.1 which is circulating now.
This is, to my knowledge, the first vaccine effectiveness estimates available worldwide for JN.1, says Ruth Link-Gelles, vaccine effectiveness program lead for COVID-19 and RSV at CDC, who led the analysis.
[
add
]
[
|
|
...
]